Encapsulated Cell Grafts to Treat Cellular Deficiencies and Dysfunction

Critical Reviews in Biomedical Engineering

Volumn 39, Issue 6, 2011, Pages 473-491

  Krishnamurthy, N V ^a   Gimi, Barjor ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cell therapy; Enzyme prodrug therapy; Immunoisolation; Islet transplantation; Microencapsulation

Indexed keywords

CYTOLOGY; DISEASE CONTROL; ENZYMES; GRAFTING (CHEMICAL); GRAFTS; MICROENCAPSULATION; POROSITY;

CELL THERAPY; CELL TRANSPLANTATION; CELLULAR DEFICIENCY; ENZYME-PRODRUG THERAPIES; IMMUNO-ISOLATION; ISLET TRANSPLANTATION; THERAPEUTIC POTENTIALS; XENOTRANSPLANTATION;

CELLS;

ALGINIC ACID; ANGIOGENESIS INHIBITOR; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; IFOSFAMIDE; PRODRUG; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALLOTRANSPLANTATION; ANTIANGIOGENIC THERAPY; CELL TRANSPLANTATION; DIABETES MELLITUS; ENZYME THERAPY; GRAFT SURVIVAL; HUMAN; HYDROGEL; MICROENCAPSULATION; MICROTECHNOLOGY; NANOFABRICATION; NANOTECHNOLOGY; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION;

EID: 84555170121     PISSN: 0278940X     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevBiomedEng.v39.i6.10     Document Type: Review

References (149)

1. Grande DA, Singh IJ, Pugh J. Healing of experimentally produced lesions in articular cartilage following chondrocyte transplantation. Anat Rec. 1987;218:142-8.
2. Carsin H, Ainaud P, Le Bever H, Rives J, Lakhel A, Stephanazzi J, Lambert F, Perrot J. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a 5-year single-center experience with 30 patients. Burns. 2000;26:379-87.
3. Fodor WL. Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate. Reprod Biol Endocrinol. 2003;1:102.
4. Chu CR, Coutts RD, Yoshioka M, Harwood FL, Monosov AZ, Amiel D. Articular cartilage repair using allogeneic perichondrocyte-seeded biodegradable porous polylactic acid (PLA): a tissue-engineering study. J Biomed Mater Res. 1995;29:1147-54.
5. Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf a human skin equivalent. Adv Wound Care. 1998;11:1-8.
6. Lacy PE. Transplantation of islet cells-isografts and allografts. Monogr Pathol. 1980;21:156-65.
7. Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185:229-40.
8. de Groot M, Schuurs TA, van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res. 2004;121:141-50.
9. Lanza RP, Cooper DK. Xenotransplantation of cells and tissues: application to a range of diseases, from diabetes to Alzheimer's. Mol Med Today. 1998;4:39-45.
10. Platt JL. Immunobiology of xenotransplantation. Transpl Int. 2000;13 Suppl 1:S7-10.
11. Boneva RS, Folks TM. Xenotransplantation and risks of zoonotic infections. Ann Med. 2004;36:504-17.
12. Bowie KM, Chang PL. Development of engineered cells for implantation in gene therapy. Adv Drug Deliv Rev. 1998;33:31-43.
13. Schwenter F, Déglon N, Aebischer P. Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy. JGene Med. 2003;5:246-57.
14. Huber A, Padrun V, Deglon N, Aebischer P, Mohler H, Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A. 2001;98:7611-6.
15. Cirone P, Bourgeois JM, Chang PL. Antiangiogenic cancer therapy with microencapsulated cells. Hum Gene Ther. 2003;14:1065-77.
16. Galli R, Borello U, Gritti A, Minasi MG, Bjornson C, Coletta M, Mora M, De Angelis MG, Fiocco R, Cossu G, Vescovi AL. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci. 2000;3:986-91.
17. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol. 2002;174:11-20.
18. Mezey E. The fate of neural crest stem cells: nature vs nurture. Mol Psychiatry. 2003;8:128-30.
19. Alam T, Sollinger HW. Glucose-regulated insulin production in hepatocytes. Transplantation. 2002;74:1781-7.
20. Goren A, Dahan N, Goren E, Baruch L, Machluf M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. Faseb J. 2010;24:22-31.
21. Bulic-Jakus F, Ulamec M, Vlahovic M, Sincic N, Katusic A, Juric-Lekc G, Serman L, Kruslin B, Belicza M. Of mice and men: teratomas and teratocarcinomas. Coll Antropol. 2006;30:921-4.
22. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-58.
23. Dean SK, Yulyana Y, Williams G, Sidhu KS, Tuch BE. Differentiation of encapsulated embryonic stem cells after transplantation. Transplantation. 2006;82:1175-84.
24. Chayosumrit M, Tuch B, Sidhu K. Alginate microcapsule for propagation and directed differentiation of hESCs to definitive endoderm. Biomaterials. 2010;31:505-14.
25. van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation. 2007;14:288-97.
26. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation. 2004;77:741-7.
27. Schmidt P, Goto M, Le Mauff B, Anegon I, Korsgren O. Adenovirus-mediated expression of human CD55 or CD59 protects adult porcine islets from complement-mediated cell lysis by human serum. Transplantation. 2003;75:697-702.
28. van der Windt DJ, Echeverri GJ, Ijzermans JN, Cooper DK. The choice of anatomical site for islet transplantation. Cell Transplantation. 2008;17:1005-14.
29. Solomon MF, Kuziel WA, Mann DA, Simeonovic CJ. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts. Xenotransplantation. 2003;10:164-77.
30. Cozzi E, Bosio E, Seveso M, Rubello D, Ancona E. Xenotransplantation as a model of integrated, multidisciplinary research. Organogenesis. 2009;5:288-96.
31. Morris PJ. A critical review of immunosuppressive regimens. TransplantProc. 1996;28:37-40.
32. Uludag H, De Vos P, Tresco PA. Technology of mammalian cell encapsulation. Adv Drug Deliv Rev. 2000;42:29-64.
33. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004;172:5143-8.
34. Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol. 2007;68:645-51.
35. Chang TMS. Semipermeable Microcapsules. Science. 1964;146:524-25.
36. Prakash S, Chang TM. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med. 1996;2:883-7.
37. Zimmermann H, Shirley SG, Zimmermann U. Alginate-based encapsulation of cells: past, present, and future. Curr Diab Rep. 2007;7:314-20.
38. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980;210:908-10.
39. De Vos P, Wolters GH, Fritschy WM, Van Schilfgaarde R. Obstacles in the application of microencapsulation in islet transplantation. The International journal of artificial organs. 1993;16:205-12.
40. Calafiore R, Basta G, Luca G, Boselli C, Bufalari A, Cassarani MP, Giustozzi GM, Brunetti P. Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians. Ann NY Acad Sci. 1999;875:219-32.
41. Wang T, Lacik I, Brissova M, Anilkumar AV, Prokop A, Hunkeler D, Green R, Shahrokhi K, Powers AC. An encapsulation system for the immunoisolation of pancreatic islets. Nat Biotechnol. 1997;15:358-62.
42. Krol S, del Guerra S, Grupillo M, Diaspro A, Gliozzi A, Marchetti P. Multilayer nanoencapsulation. New approach for immune protection of human pancreatic islets. Nano Lett. 2006;6:1933-9.
43. Weber LM, Cheung CY, Anseth KS. Multifunctional Pancreatic Islet Encapsulation Barriers Achieved Via Multilayer PEG Hydrogels. Cell Transplantation. 2007;16:1049-57.
44. Zimmermann H, Hillgartner M, Manz B, Feilen P, Brunnenmeier F, Leinfelder U, Weber M, Cramer H, Schneider S, Hendrich C, Volke F, Zimmermann U. Fabrication of homogeneously cross-linked, functional alginate microcapsules validated by NMR-, CLSM-and AFM-imaging. Biomaterials. 2003;24:2083-96.
45. Martinsen A, Storro I, Skjark-Braek G. Alginate as immobilization material: III. Diffusional properties. Biotechnol Bioeng. 1992;39:186-94.
46. de Vos P, Vegter D, Strubbe JH, de Haan BJ, van Schilfgaarde R. Impaired glucose tolerance in recipients of an intraperitoneally implanted microencapsulated islet allograft is caused by the slow diffusion of insulin through the peritoneal membrane. TransplantProc. 1997;29:756-7.
47. Sefton MV, May MH, Lahooti S, Babensee JE. Making microencapsulation work: conformal coating, immobilization gels and in vivo performance. J Control Release. 2000;65:173-86.
48. Wyman JL, Kizilel S, Skarbek R, Zhao X, Connors M, Dillmore WS, Murphy WL, Mrksich M, Nagel SR, Garfinkel MR. Immunoisolating pancreatic islets by encapsulation with selective withdrawal. Small. 2007;3:683-90.
49. Bhatia SR, Khattak SF, Roberts SC. Polyelectrolytes for cell encapsulation. Current Opinion in Colloid & Interface Science. 2005;10:45-51.
50. Hunt NC, Grover LM. Cell encapsulation using biopolymer gels for regenerative medicine. Biotechn Lett. 2010;32:733-42.
51. Santos E, Zarate J, Orive G, Hernandez RM, Pedraz JL. Biomaterials in cell microencapsulation. Adv ExplMed Biol. 2010;670:5-21.
52. Wen-Hwa C, Chin R, Huen T, Ferrari M. Silicon membrane nanofilters from sacrificial oxide removal. J Microelectromech Sys. 1999;8:34-42.
53. Desai TA, Chu WH, Rasi G, Sinibaldi-Vallebona P, Guarino E, Ferrari M. Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts. Biomedical Microdevices. 1999;1:131-8.
54. Desai TA, Hansford D, Ferrari M. Characterization of micromachined silicon membranes for immunoisolation and bioseparation applications. J Membrane Sci. 1999;159:221-31.
55. Gong D, Yadavalli V, Paulose M, Pishko M, Grimes CA. Controlled Molecular Release Using Nanoporous Alumina Capsules. Biomedical Microdevices. 2003;5:75-80.
56. Gimi B, Kwon J, Liu L, Su Y, Nemani K, Trivedi K, Cui Y, Vachha B, Mason R, Hu W, Lee JB. Cell encapsulation and oxygenation in nanoporous microcontainers. Biomedical Microdevices. 2009;11:1205-12.
57. Kwon J, Trivedi K, Krishnamurthy NV, Hu W, Lee J-B, Gimi B. SU-8-based immunoisolative microcontainer with nanoslots defined by nanoimprint lithography. J Vac Sci Technol B Microelectron Nanometer Struct Process Meas Phenom. 2009;27:2795-800.
58. Leoni L, Desai TA. Micromachined biocapsules for cell-based sensing and delivery. Adv Drug Deliv Rev. 2004;56:211-29.
59. Leoni L, Boiarski A, Desai TA. Characterization of nanoporous membranes for immunoisolation: diffusion properties and tissue effects. Biomedical Microdevices. 2002;4:131-39.
60. Iwata H, Morikawa N, Fujii T, Takagi T, Samejima T, Ikada Y. Does immunoisolation need to prevent the passage of antibodies and complements? Transplant Proc. 1995;27:3224-6.
61. Suzuki K, Bonner-Weir S, Trivedi N, Yoon KH, Hollister-Lock J, Colton CK, Weir GC. Function and survival of macroencapsulated syngeneic islets transplanted into streptozocin-diabetic mice. Transplantation. 1998;66:21-8.
62. Kang J, Erdodi G, Yalcin B, Cakmak M, Kennedy JP. POLY 591-Bioartificial pancreas: A novel macro-immunoisolatory device. Abstracts of the 235th ACS National Meeting, Polymer Preprints. 2008;49:824-825.
63. Kang J, Erdodi G, Kennedy JP, Chou H, Lu LN, Grundfest-Broniatowski S. Toward a bioartificial pancreas: diffusion of insulin and IgG across immunoprotective membranes with controlled hydrophilic channel diameters. Macromolecular Bioscience. 2010;10:369-77.
64. Sun AM, Parisius W, Healy GM, Vacek I, Macmorine HG. The use, in diabetic rats and monkeys, of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas). Diabetes. 1977;26:1136-9.
65. Lanza RP, Sullivan SJ, Chick WL. Perspectives in diabetes. Islet transplantation with immunoisolation. Diabetes. 1992;41:1503-10.
66. Lanza RP, Solomon BA, Monaco AP, Chick WL. Devices implanted as AV shunts. In: Lanza RP, Chick WL, eds. Pancreatic islet transplantation: Volume III Immunoisolation of pancreatic islets. Austin, TX: Landes/CRC Press; 1994. pp. 154-68.
67. Maki T, Otsu I, O'Neil JJ, Dunleavy K, Mullon CJ, Solomon BA, Monaco AP. Treatment of diabetes by xenogeneic islets without immunosuppression. Use of a vascularized bioartificial pancreas. Diabetes. 1996;45:342-7.
68. Shoichet MS, Rein DH. In vivo biostability of a polymeric hollow fibre membrane for cell encapsulation. Biomaterials. 1996;17:285-90.
69. Lanza RP, Butler DH, Borland KM, Staruk JE, Faustman DL, Solomon BA, Muller TE, Rupp RG, Maki T, Monaco AP, Chick WL. Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. Proc Natl Acad Sci U S A. 1991;88:11100-4.
70. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103:3896-901.
71. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther. 2008;10:506-15.
72. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35-9.
73. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery. 1972;72:175-86.
74. Calafiore R, Basta G, Osticioli L, Luca G, Tortoioli C, Brunetti P. Coherent microcapsules for pancreatic islet transplantation: a new approach for bioartificial pancreas. Transplant Proc. 1996;28:812-3.
75. Soon-Shiong P. Treatment of type I diabetes using encapsulated islets. Adv Drug Deliv Rev. 1999;35:259-70.
76. Zhou D, Kintsourashvili E, Mamujee S, Vacek I, Sun AM. Bioartificial pancreas: alternative supply of insulin-secreting cells. Ann New York Acad Sci. 1999;875:208-18.
77. Kizilel S, Garfinkel M, Opara E. The bioartificial pancreas: progress and challenges. Diabetes Technol Ther. 2005;7:968-85.
78. Fort A, Fort N, Ricordi C, Stabler CL. Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. Cell transplantation. 2008;17:997-1003.
79. Kobayashi N. Bioartificial pancreas for the treatment of diabetes. Cell Transplant. 2008;17:11-17.
80. Opara EC, Mirmalek-Sani SH, Khanna O, Moya ML, Brey EM. Design of a bioartificial pancreas(+). J Investig Med. 2010;58:831-7.
81. Vaithilingam V, Oberholzer J, Guillemin GJ, Tuch BE. The humanized NOD/SCID mouse as a preclinical model to study the fate of encapsulated human islets. Rev Diabet Stud. 2010;7:62-73.
82. Teramura Y, Iwata H. Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. Adv Drug Deliv Rev. 2010;62:827-40.
83. de Vos P, Spasojevic M, Faas MM. Treatment of Diabetes with Encapsulated Islets. Ther Appl Cell Microencap. 2010;670:38-53.
84. Home PD, Massi-Benedetti M, Shepherd GA, Hanning I, Alberti KG, Owens DR. A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. Diabetologia. 1982;22:41-5.
85. Korbutt GS, Ao Z, Flashner M, Rajotte RV. Neonatal porcine islets as a possible source of tissue for humans and microencapsulation improves the metabolic response of islet graft posttransplantation. Ann New York Acad Sci. 1997;831:294-303.
86. Andersson A, Groth CG, Korsgren O, Tibell A, Tollemar J, Kumagai M, Moller E, Bolinder J, Ostman J, Bjoersdorff A, Hellerstrom C. Transplantation of porcine fetal islet-like cell clusters to three diabetic patients. Transplant Proc. 1992;24:677-8.
87. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, Vasconcellos AV, Emerich DF, Thanos C, Bambra C. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc. 2005;37:3505-8.
88. Weir GC. Can we make surrogate beta-cells better than the original? Semin Cell Dev Biol. 2004;15:347-57.
89. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol. 2005;23:857-61.
90. Gonez LJ, Knight KR. Cell therapy for diabetes: stem cells, progenitors or beta-cell replication? Mol Cell Endocrinol. 2010;323:55-61.
91. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
92. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653-9.
93. Rosenberg L, Lipsett M, Yoon JW, Prentki M, Wang R, Jun HS, Pittenger GL, Taylor-Fishwick D, Vinik AI. A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. Ann Surg. 2004;240:875-84.
94. Blyszczuk P, Czyz J, Kania G, Wagner M, Roll U, St-Onge L, Wobus AM. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci U S A. 2003;100:998-1003.
95. Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49:157-62.
96. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes. 2001;50:1691-7.
97. Kubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, Fehling HJ, Keller G. Development of definitive endoderm from embryonic stem cells in culture. Development. 2004;131:1651-62.
98. D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol. 2005;23:1534-41.
99. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24:1392-401.
100. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.
101. Ricci M, Blasi P, Giovagnoli S, Rossi C, Macchiarulo G, Luca G, Basta G, Calafiore R. Ketoprofen controlled release from composite microcapsules for cell encapsulation: effect on post-transplant acute inflammation. J Control Release. 2005;107:395-407.
102. Luca G, Nastruzzi C, Basta G, Brozzetti A, Saturni A, Mughetti D, Ricci M, Rossi C, Brunetti P, Calafiore R. Effects of anti-oxidizing vitamins on in vitro cultured porcine neonatal pancreatic islet cells. Diabetes Nutr Metab. 2000;13:301-7.
103. Tzakis AG, Ricordi C, Alejandro R, Zeng Y, Fung JJ, Todo S, Demetris AJ, Mintz DH, Starzl TE. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336:402-5.
104. Ricordi C. Lilly lecture 2002-Islet transplantation: A brave new world. Diabetes. 2003;52:1595-603.
105. Ricordi C, Strom TB. Clinical islet transplantation: Advances and immunological challenges. Nat Rev Immunol. 2004;4:258-68.
106. Kenyon NS, Ranuncoli A, Masetti M, Chatzipetrou M, Ricordi C. Islet transplantation: present and future perspectives. Diabetes Metab Rev. 1998;14:303-13.
107. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory Effects of Immunosuppressive Drugs on Insulin Secretion From Hit-T15 Cells and Wistar Rat Islets1. Transplantation. 2002;73:353-57.
108. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-8.
109. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes. 2002;51:2148-57.
110. Shapiro AMJ, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems J-A, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DER, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JRT. International Trial of the Edmonton Protocol for Islet Transplantation. New Engl J Med. 2006;355:1318-30.
111. Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, Racanicchi L, Mancuso F, Brunetti P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29:137-8.
112. Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32:1887-9.
113. Foster JL, Williams G, Williams LJ, Tuch BE. Differentiation of transplanted microencapsulated fetal pancreatic cells. Transplantation. 2007;83:1440-8.
114. Hering BJ, Wijkstrom M, Graham ML, Hardstedt M, Aasheim TC, Jie T, Ansite JD, Nakano M, Cheng J, Li W, Moran K, Christians U, Finnegan C, Mills CD, Sutherland DE, Bansal-Pakala P, Murtaugh MP, Kirchhof N, Schuurman HJ. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 2006;12:301-3.
115. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 2007;14:157-61.
116. Elliott RB, Garkavenko O, Tan P, Skaletsky NN, Guliev A, Draznin B. Transplantation of microencapsulated neonatal porcine islets in patients with type 1 diabetes: safety and efficacy. (Abstract number 161-OR) Abstracts of the 70th Scientific Sessions of American Diabetes Association; Diabetes 2010; 59 (supplement-1).
117. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000;2:148-64.
118. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7:3314-24.
119. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004;56:53-102.
120. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 2008;270:191-201.
121. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996;3:173-8.
122. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002;9:291-6.
123. Kaliberova LN, Della Manna DL, Krendelchtchikova V, Black ME, Buchsbaum DJ, Kaliberov SA. Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther. 2008;7:2845-54.
124. Fuchita M, Ardiani A, Zhao L, Serve K, Stoddard BL, Black ME. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res. 2009;69:4791-9.
125. Cirone P, Potter M, Hirte H, Chang P. Immuno-isolation in cancer gene therapy. Curr Gene Ther. 2006;6:181-91.
126. Gunzburg WH, Salmons B. Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol Med. 2001;7:30-7.
127. Lohr M, Hummel F, Faulmann G, Ringel J, Saller R, Hain J, Gunzburg WH, Salmons B. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother Pharmacol. 2002;49 (Suppl 1):S21-4.
128. Gunzburg WH, Salmons B. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer. Acta Biochim Pol. 2005;52:601-7.
129. Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Saller R, Hafner M, Sturm J, Post S, Lohr M. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther. 2006;13:65-73.
130. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001;19:35-9.
131. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol. 2001;19:29-34.
132. Rodrigues DB, Chammas R, Malavasi NV, da Costa PL, Chura-Chambi RM, Balduino KN, Morganti L. Anti-tumor therapy with macroencapsulated endostatin producer cells. BMC Biotechnol. 2010;10:19.
133. Cirone P, Bourgeois JM, Shen F, Chang PL. Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Hum Gene Ther. 2004;15:945-59.
134. Cirone P, Shen F, Chang PL. A multiprong approach to cancer gene therapy by coencapsulated cells. Cancer Gene Ther. 2005;12:369-80.
135. Hao S, Su L, Guo X, Moyana T, Xiang J. A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells. Exp Oncol. 2005;27:56-60.
136. Salmons B, Lohr M, Gunzburg WH. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J Gastroenterol. 2003;38 Suppl 15:78-84.
137. Wen J, Xu N, Li A, Bourgeois J, Ofosu FA, Hortelano G. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. J Gene Med. 2007;9:1002-10.
138. Murua A, de Castro M, Orive G, Hernandez RM, Pedraz JL. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-L-lysine-alginate microcapsules. Biomacromolecules. 2007;8:3302-7.
139. Cheng WT, Chen BC, Chiou ST, Chen CM. Use of nonautologous microencapsulated fibroblasts in growth hormone gene therapy to improve growth of midget swine. Hum Gene Ther. 1998;9:1995-2003.
140. Visted T, Bjerkvig R, Enger PO. Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro Oncol. 2001;3:201-10.
141. Emerich DF, Winn SR. Immunoisolation cell therapy for CNS diseases. Crit Rev Ther Drug Carrier Syst. 2001;18:265-98.
142. Hasse C, Bohrer T, Barth P, Stinner B, Cohen R, Cramer H, Zimmermann U, Rothmund M. Parathyroid xenotransplantation without immunosuppression in experimental hypoparathyroidism: long-term in vivo function following microencapsulation with a clinically suitable alginate. World J Surg. 2000;24:1361-6.
143. Sun AM, Cai Z, Shi Z, Ma F, O'Shea GM, Gharapetian H. Microencapsulated hepatocytes as a bioartificial liver. ASAIO Trans. 1986;32:39-41.
144. Winn SR, Emerich DF. Managing chronic pain with encapsulated cell implants releasing catecholamines and endogenous opiods. Front Biosci. 2005;10:367-78.
145. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol. 2008;209:82-8.
146. Lindner MD, Emerich DF. Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease. Cell transplantation. 1998;7:165-74.
147. Garcia P, Youssef I, Utvik JK, Florent-Bechard S, Barthelemy V, Malaplate-Armand C, Kriem B, Stenger C, Koziel V, Olivier JL, Escanye MC, Hanse M, Allouche A, Desbene C, Yen FT, Bjerkvig R, Oster T, Niclou SP, Pillot T. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci. 2010;30:7516-27.
148. Fjord-Larsen L, Kusk P, Tornoe J, Juliusson B, Torp M, Bjarkam CR, Nielsen MS, Handberg A, Sorensen JC, Wahlberg LU. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Gottingen Minipig Basal Forebrain. Mol Ther. 2010;18:2164-72.
149. Renggli-Zulliger N, Dudler J, Fujimoto N, Iwata K, So A. Use of encapsulated cells secreting murine TIMP-2 ameliorates collagen-induced arthritis in mice. Ann NY Acad Sci. 1999;878:515-8.